Kevin Hicok

Kevin Hicok is an accomplished professional in the field of research and development, currently serving as Vice President of Research and Development at Direct Biologics since October 2019, leading a team that achieved Phase III clinical trial status for the first extracellular vesicle therapeutic in the US. Hicok has extensive experience in the biotechnology sector, including previous roles as Vice President of Intellectual Property and Innovation and Vice President of Research and Development at KCH-Cell-Tx Consulting. Notable contributions include the development of innovative therapeutics for COVID-19 ARDS and the establishment of laboratory processes for regenerative cell isolation at Gallant Inc. Hicok's background features significant achievements in cell agriculture, regenerative medicine, and molecular characterization, supported by an educational foundation that includes an MS in Cell and Developmental Biology from the University of Minnesota.